BI 1026706

Drug Profile

BI 1026706

Alternative Names: BI-1026706

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema
  • Phase I Chronic obstructive pulmonary disease; Osteoarthritis; Postoperative pain

Most Recent Events

  • 01 Mar 2017 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02657408)
  • 01 Dec 2016 Boehringer Ingelheim completes a phase I trial in Chronic obstructive pulmonary disease (In volunteers) in Japan (NCT02652416)
  • 30 Jun 2016 Boehringer Ingelheim completes a phase I trial for Chronic obstructive pulmonary disease in Germany, Sweden, Denmark and United Kingdom (PO) (NCT02642614)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top